Therapeutic proteins : strategies to modulate their plasma half-lives /
For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The...
| Άλλοι συγγραφείς: | |
|---|---|
| Μορφή: | Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Weinheim, Germany :
Wiley-Blackwell, an imprint of John Wiley & Sons,
2012.
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- General information
- Half-life modulating strategies : an introduction
- Pharmacokinetics and half-life of protein therapeutics
- Half-life extension through chemical and post-translational modifications
- Half-life extension through PEGylation
- Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics
- Half-life extension through O-glycosylation
- Polysialic acid and polysialylation to modulate antibody pharmacokinetics
- Half-life extension through HESylation
- Half-life modulation involving recycling by the neonatal Fc receptor
- The biology of the neonatal Fc receptor (FcRn)
- half-life extension by fusion to the Fc region
- Monomeric Fc fusion technology: an approach to create long-lasting clotting factors
- The diverse roles of FcRn: implications for antibody engineering
- Half-life extension by fusion to recombinant albumin
- AlbudAb technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives
- Half-life extension by binding to albumin through an albumin binding domain
- Half-life extension by binding to albumin through small molecules
- Half-life extension with pharmaceutical formulations
- Half-life extension with pharmaceutical formulations: liposomes
- Half-life extension with pharmaceutical formulations: nanoparticles by the miniemulsion process.
